APA (7th ed.) Citation

Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., . . . Antonia, S. J. (2017). Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncology, 18(1), 31. https://doi.org/10.1016/S1470-2045(16)30624-6

Chicago Style (17th ed.) Citation

Hellmann, Matthew D., et al. "Nivolumab Plus Ipilimumab as First-line Treatment for Advanced Non-small-cell Lung Cancer (CheckMate 012): Results of an Open-label, Phase 1, Multicohort Study." Lancet Oncology 18, no. 1 (2017): 31. https://doi.org/10.1016/S1470-2045(16)30624-6.

MLA (9th ed.) Citation

Hellmann, Matthew D., et al. "Nivolumab Plus Ipilimumab as First-line Treatment for Advanced Non-small-cell Lung Cancer (CheckMate 012): Results of an Open-label, Phase 1, Multicohort Study." Lancet Oncology, vol. 18, no. 1, 2017, p. 31, https://doi.org/10.1016/S1470-2045(16)30624-6.